公开(公告)号：US20240150309A1

公开(公告)日：2024-05-09

申请号：US18501481

申请日：2023-11-03

申请人： Daiichi Sankyo Company, Limited

发明人： Keiji Saito ,  Katsuyoshi Nakajima ,  Toru Taniguchi ,  Osamu Iwamoto ,  Satoshi Shibuya ,  Yasuyuki Ogawa ,  Kazumasa Aoki ,  Nobuya Kurikawa ,  Shinji Tanaka ,  Momoko Ogitani ,  Eriko Kioi ,  Kaori Ito ,  Natsumi Nishihama ,  Tsuyoshi Mikkaichi ,  Wataru Saitoh

IPC分类号： C07D307/94 ,  A61K31/343 ,  A61K31/4155 ,  A61K31/4245 ,  C07D405/04 ,  C07D405/10 ,  C07D407/12 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14

CPC分类号： C07D307/94 ,  A61K31/343 ,  A61K31/4155 ,  A61K31/4245 ,  C07D405/04 ,  C07D405/10 ,  C07D407/12 ,  C07D413/04 ,  C07D413/10 ,  C07D413/14

摘要： An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof.
The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof.




wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.

公开(公告)号：US20240092789A1

公开(公告)日：2024-03-21

申请号：US17766289

申请日：2020-09-16

申请人： Merck Patent GmbH

发明人： Elvira MONTENEGRO ,  Teresa MUJICA-FERNAUD ,  Rachel TUFFIN ,  Frank VOGES ,  Amir Hossain PARHAM ,  Alexander Christian COMELY ,  Antoni MORAGAS SOLA

IPC分类号： C07D487/10 ,  C07D209/70 ,  C07D307/94 ,  C07D333/78 ,  H10K50/11 ,  H10K50/15 ,  H10K85/60

CPC分类号： C07D487/10 ,  C07D209/70 ,  C07D307/94 ,  C07D333/78 ,  H10K50/11 ,  H10K50/15 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576

摘要： The present application relates to a compound of the formula (I), to the use thereof in electronic devices, to processes for preparing the compound, and electronic devices comprising the compound.

公开(公告)号：US11691980B2

公开(公告)日：2023-07-04

申请号：US16610165

申请日：2018-05-01

申请人： TOHOKU UNIVERSITY

发明人： Ken Saijo ,  Chikashi Ishioka ,  Tadashi Katoh ,  Koichi Narita

IPC分类号： C07D409/04 ,  C07D307/93 ,  C07D317/64 ,  C07C47/57 ,  C07D307/94 ,  C07D493/04

CPC分类号： C07D493/04 ,  C07C47/57 ,  C07D307/93 ,  C07D307/94 ,  C07D317/64

摘要： A method of treating a disease that is treatable through inhibition of at least one kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2, TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the method comprising administering an effective dose of a compound represented by the following formula (1) or a salt thereof to a patient:

公开(公告)号：US20190192516A1

公开(公告)日：2019-06-27

申请号：US16285996

申请日：2019-02-26

申请人： AUTIFONY THERAPEUTICS LIMITED

发明人： Giuseppe ALVARO ,  Paolo DAMBRUOSO ,  Simona TOMMASI ,  Anne DECOR ,  Charles LARGE ,  Agostino MARASCO

IPC分类号： A61K31/506 ,  C07D317/46 ,  C07D405/14 ,  C07D307/94 ,  A61K31/4439 ,  C07D413/14 ,  C07D413/12 ,  C07D405/12 ,  C07D307/79

CPC分类号： A61K31/506 ,  A61K31/4439 ,  C07D307/79 ,  C07D307/94 ,  C07D317/46 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14

摘要： The disclosure provides compounds of formula (I): said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.

公开(公告)号：US20180251441A1

公开(公告)日：2018-09-06

申请号：US15756788

申请日：2016-09-01

申请人： HOWARD HUGHES MEDICAL INSTITUTE

发明人： Luke D. LAVIS ,  Jonathan B. GRIMM ,  Laurel M. HECKMAN ,  Eric R. SCHREITER

IPC分类号： C07D311/16 ,  C09K11/06 ,  C07D311/82 ,  C07D405/12 ,  C07D307/94 ,  A61K41/00 ,  A61N5/06 ,  G01N21/64

CPC分类号： C07D311/16 ,  A61K41/0057 ,  A61N5/06 ,  A61N5/062 ,  C07D307/94 ,  C07D311/82 ,  C07D405/12 ,  C09K11/06 ,  C09K2211/1022 ,  G01N21/6428 ,  G01N33/582 ,  G01N33/84 ,  G01N2021/6439

摘要： The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R1 is selected from H, halogen, alkyl, and acyl; each R2 is independently selected from H, alkyl, aryl, and acyl, and is optionally substituted with one or more heteroatoms independently selected from COOH and COO(alkyl); and R3 is selected from H, alkyl, aryl, halogen, CN, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, CHO, COOH, COO(alkyl), COO(aryl), PO3H2, and SO3H, and is optionally substituted with one or more heteroatoms independently selected from N, O, and S, halogen, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, NO2, CHO, COO, COOH, COO(alkyl), COO(aryl), C(O)NR2, PO3H2, and/or SO3H. Also provided are methods of detecting calcium and treating a subject with the analyte-activated photolabile compounds.

公开(公告)号：US20180221365A1

公开(公告)日：2018-08-09

申请号：US15573504

申请日：2016-05-11

申请人： Temple University-Of The Commonwealth System of Higher Education

发明人： Daniel J. Canney ,  Benjamin E. Blass ,  Rong Gao ,  Kevin Blattner

IPC分类号： A61K31/496 ,  A61K31/4709 ,  A61K31/4525 ,  A61K31/4725 ,  A61P35/00

CPC分类号： A61K31/496 ,  A61K31/4525 ,  A61K31/4709 ,  A61K31/4725 ,  A61P35/00 ,  C07D307/33 ,  C07D307/94 ,  C07D405/02 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

摘要： Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.

公开(公告)号：US20180036308A1

公开(公告)日：2018-02-08

申请号：US15730559

申请日：2017-10-11

申请人： AUTIFONY THERAPEUTICS LIMITED

发明人： Giuseppe ALVARO ,  Agostino MARASCO

IPC分类号： A61K31/506 ,  C07D413/12 ,  C07D405/14 ,  C07D405/12 ,  C07D317/46 ,  C07D307/94 ,  C07D307/79 ,  C07D413/14 ,  A61K31/4439

CPC分类号： A61K31/506 ,  A61K31/4439 ,  C07D307/79 ,  C07D307/94 ,  C07D317/46 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D413/14

摘要： Methods for the treatment of Fragile X that includes administering to a subject in need thereof a compound of formula (I): are described herein.

公开(公告)号：US20180016261A1

公开(公告)日：2018-01-18

申请号：US15716752

申请日：2017-09-27

申请人： TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Daniel J. CANNEY ,  Benjamin E. BLASS ,  Rong GAO ,  Magid ABOU-GHARBIA

IPC分类号： C07D405/12 ,  C07D307/33 ,  C07D307/94 ,  C07D405/06

CPC分类号： C07D405/12 ,  C07D307/33 ,  C07D307/94 ,  C07D405/06

摘要： Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

公开(公告)号：US20180006244A1

公开(公告)日：2018-01-04

申请号：US15543192

申请日：2016-01-08

申请人： SFC CO., LTD.

发明人： Soon-Wook CHA ,  Sang-woo PARK ,  Seok-Bae PARK ,  Hee-Dae KIM

IPC分类号： H01L51/00 ,  C07D333/78 ,  C07D495/10 ,  C07D307/93 ,  C09K11/02 ,  C07D307/94 ,  C07D493/10 ,  H01L51/50

CPC分类号： H01L51/0073 ,  C07D307/93 ,  C07D307/94 ,  C07D333/78 ,  C07D493/10 ,  C07D495/10 ,  C09K11/025 ,  C09K11/06 ,  H01L51/0052 ,  H01L51/0058 ,  H01L51/0074 ,  H01L51/50 ,  H01L51/5012 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5088 ,  H01L51/5092

摘要： The present invention relates to a novel anthracene derivative, for an organic light-emitting device, and an organic light-emitting device comprising same, the anthracene derivative enabling excellent device characteristics when used as a light-emitting material.

公开(公告)号：US20180002308A1

公开(公告)日：2018-01-04

申请号：US15542216

申请日：2016-01-08

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Masaki ASADA ,  Kousuke TANI ,  Masaya HIROBE ,  Satonori HIGUCHI ,  Kazuhiro FUCHIBE ,  Ryo OIKAWA ,  Tohru KOTANI ,  Hirotsugu TAKANO

IPC分类号： C07D311/96 ,  C07D417/12 ,  C07D417/04 ,  C07D413/12 ,  C07D413/04 ,  C07D409/04 ,  C07D407/12 ,  C07D405/14 ,  C07D405/12 ,  C07D405/04 ,  C07D401/04 ,  C07D231/40 ,  C07D213/40 ,  C07C255/60 ,  A61K45/06 ,  A61K31/5383 ,  A61K31/501 ,  A61K31/496 ,  A61K31/4439 ,  A61K31/4433 ,  A61K31/4427 ,  A61K31/4406 ,  A61K31/427 ,  A61K31/4245 ,  A61K31/422 ,  A61K31/4192 ,  A61K31/4155 ,  A61K31/415 ,  A61K31/4025 ,  A61K31/397 ,  A61K31/381 ,  A61K31/352 ,  A61K31/277 ,  A61K9/20 ,  C07D498/04 ,  C07C2603/94

CPC分类号： C07D311/96 ,  A61K9/20 ,  A61K31/277 ,  A61K31/343 ,  A61K31/352 ,  A61K31/381 ,  A61K31/397 ,  A61K31/4025 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4192 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/453 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5383 ,  A61K33/24 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  C07C255/60 ,  C07C255/63 ,  C07C2603/94 ,  C07D213/40 ,  C07D213/56 ,  C07D231/12 ,  C07D231/40 ,  C07D307/94 ,  C07D401/04 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/04 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04 ,  C07D498/04

摘要： A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.